恩替卡韦联合百令胶囊治疗对干扰素α-2b无应答的HBeAg 阳性的慢性乙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2018.01.027

Abstract

Deng Weiping, Ma Deqiang, Zheng Hongmei, et a1. Combination of entecavir and Bailing capsule in the treatment of HBeAg positive chronic hepatitis B patients without response to interferon alpha-2b therapy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 110-111.

References

[1] Yao JY,Chao K,Li MR,et a1. Interleukin-21 gene polymorphisms and chronic hepatitis B infection in a Chinese population. World J Gastroenterol,2015,21（14）：4232-4239.
[2] 陈雅萍,张勤俭,田楠楠.恩替卡韦联合聚乙二醇干扰素治疗慢性乙型肝炎患者疗效观察.实用肝脏病杂志,2016,19（2）：208-209.
[3] Yeh ML,Peng CY,Dai CY,et a1. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One,2015,10（4）：e0122259.
[4] 王丽曼,张鸿飞,董漪. 干扰素治疗慢性乙型肝炎儿童诱发甲状腺功能紊乱的临床研究. 中华临床医师杂志（电子版）,2014,8（24）：52-55.
[5] Marcellin P,Asselah T. Long-term therapy for chronic hepatitis B：hepatitis B virus DNA suppression leading to cirrhosis reversa1. J Castroenterol Hepatol,2013,28（6）：912-923.
[6] 参加慢性乙型肝炎长期治疗讨论会专家.核苷和核苷酸类药物洽疗慢性乙型肝炎的长期性. 实用肝脏病杂志,2015,l8（1）：I-VIII.
[7] 李龙珠,刘家军,郭俐宏.百令胶囊对大鼠肝移植后肝肾功能影响的实验研究. 世界中医药,2016,11（1）：127-130.
[8] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志,2016,19（3）：Ⅴ-ⅩⅩⅢ.
[9] 柴艳云,李建国,金磊. 乙型肝炎肝硬化患者外周血补体和 T 淋巴细胞计数的变化. 实用肝脏病杂志,2016,19（6）：724-725.
[10] 沈显元,陈金香,喻春红. 血清 HBsAg 定量变化预测干扰素α-2b治疗慢性乙型肝炎停药后疗效研究.实用肝脏病杂志,2016,19（4）：476-477.
[11] 汪梦,汤雄,张竟,等. 恩替卡韦治疗儿童慢性乙型肝炎的疗效.实用临床医学,2012,13（1）：16-18.
[12] 申恩华,杜娟,王立红. 血清 HBsAg载量反映恩替卡韦治疗乙型肝炎肝硬化合并原发性肝癌患者病毒应答的临床价值.中国医药导报,2016,13（17）：86-88.
[13] 李晨,游绍莉,吕飒. 恩替卡韦导致乙型肝炎肝硬化患者周围神经病变临床特征. 实用肝脏病杂志,2016,19（2）：200-203.
[14] Fung L,Seto WK,Lai CL,et a1. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol,2014,29（3）：428-434.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[8]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[9]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[10]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[14]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[15]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.

Combination of entecavir and Bailing capsule in the treatment of HBeAg positive chronic hepatitis B patients without response to interferon alpha-2b therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments